3 results
Approved WMOCompleted
To assess the safety and tolerability of escalating single IV doses of NI-0801.To determine the pharmacokinetics and pharmacodynamics parameters of escalating single IV doses of NI-0801.
Approved WMOCompleted
Primary objective: • To assess the pharmacokinetics of DOR in patients prior to and after BSSecondary objectives: • To assess the safety of DOR in patients prior to and after undergoing BS• To assess the viral response to DOR in patients prior to…
Approved WMOCompleted
To determine the activity (as measured by objective response rate by RECIST1.1) of monalizumab and trastuzumab in patients with metastatic HER2-positive breast cancer.